Comprehensive Analysis of High Blood Pressure Treatment Guidelines

This report analyzes high blood pressure treatment based on three articles. The overarching theme revolves around hypertension and its management. The report focuses on the Whelton PK et al. (2017) guideline, highlighting its comprehensive approach to preventing, detecting, evaluating, and managing hypertension compared to JNC7. It also explores how the guideline informs clinical practice, including the treatment of pregnant women and patients with specific conditions. Susannah's discussion underscores the guideline's role in recommending against continued Prinzide therapy due to hydrochlorothiazide's pregnancy category B status. Rhonda's argument, also based on the guideline, emphasizes the need for careful monitoring of pregnant women and the use of ACE inhibitors. The report references key publications like those by James et al. (2014), Go et al. (2014), and Egan (2015), demonstrating a clear understanding of the relevant medical literature. The report effectively summarizes the implications of the guideline in clinical scenarios and highlights the importance of adhering to the guideline's recommendations for patient care.

Running head: HIGH BLOOD PRESSURE TREATMENT 1
High Blood Pressure Treatment
Name
Institution

HIGH BLOOD PRESSURE TREATMENT 2
According to the three articles, the overarching theme is the high blood pressure.
According to the Whelton PK et al. (2017 High Blood Pressure Clinical Practice Guideline), I
have been able to learn that the establishment of the guideline to help tackle the BP as a source
for both clinical and public health practice communities. From this guideline, I have been able to
recognize that it was designed to be comprehensive yet succinct as well as providing in the
provision of guidance for preventing, detecting, evaluating, and managing hypertensions. I have
further learned that this guideline is a more effective one in dealing with BP as compared to the
JNC7 because it has incorporated novel info from researches of office-oriented BP-linked risks
of cardiovascular disease, ambulatory BP monitoring, home BP monitoring, telemedicine
alongside a range of areas. However, I have as well understood that the guideline doesn’t address
the utilization of BP-decreasing medication for repeated CVD events prevention in stable
ischemic heart illness and chronic heart failure patients without hypertensions. The guideline has
shown effectively how to apply class of recommendations alongside level of evidence to clinical
strategies, interventions, treatment and diagnostic testing in caring for BP patients (James et al.
2014).
According to the discussion by Susannah, it can be clearly seen how she used the
guideline in addressing the treatment of BP patient. It is through the application of the guideline
that Susannah is able to conclude that it remains contraindicated for BP to continue the present
Prinzide therapy because as provided for in the guideline, hydrochlorothiazide remains a
pregnancy category B. I have as well learned that the discussion by Susannah is anchored on the
use of the guideline to inform her recommendation that antihypertensive medication could be
safely withheld in women with chronic hypertension history. Just as provided for in the

HIGH BLOOD PRESSURE TREATMENT 3
guideline, Susannah seems to have strictly adhered to its provision. This is why she says that she
would start by assessing the BD for any history of depression since it is suggested in the
guideline that methyldopa might be prevented in women with past history due to potential
augmented risk of postnatal depression.
According to the discussion by Rhonda, she also based argument on the provision of the
guideline. This is seen when she identifies BD as a pregnant women and hence saying that there
might be contraindications pharmacology in her BP treatment (Go et al., 2014). Thus, she says
correctly that based on BD’s high BP, she is able to be removed from her hypertensive
medications as well as monitored closely in the course of 1st trimester half of pregnancy because
of physiological fall in BP (Egan, 2015). In essence, this is what the guideline has provided for
and hence it can be said that Rhonda has strictly followed the provision of the guideline in her
argument. It is, therefore, right for Rhonda to conclude that it remains significant to monitor
BUN and Creatinine alongside electrolyte when BD is taking ACE inhibitors.

HIGH BLOOD PRESSURE TREATMENT 4
References
Egan, B. M. (2015). Treatment resistant hypertension. Ethnicity & disease, 25(4), 495.
Go, A. S., Bauman, M. A., King, S. M. C., Fonarow, G. C., Lawrence, W., Williams, K. A., &
Sanchez, E. (2014). An effective approach to high blood pressure control: a science
advisory from the American Heart Association, the American College of Cardiology, and
the Centers for Disease Control and Prevention. Hypertension, 63(4), 878-885.
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler,
J., ... & Smith, S. C. (2014). 2014 evidence-based guideline for the management of high
blood pressure in adults: report from the panel members appointed to the Eighth Joint
National Committee (JNC 8). Jama, 311(5), 507-520.